前列腺特异性抗原（PSA）筛查中的争议。 - Suppr

Suppr

超能文献

Controversies in PSA screening.

作者信息

O'Sullivan Jack

出版信息

Evid Based Med. 2017 Dec;22(6):198. doi: 10.1136/ebmed-2017-110858. Epub 2017 Nov 9.

DOI:10.1136/ebmed-2017-110858

PMID:29122825

Abstract

摘要

相似文献

Controversies in PSA screening.

Evid Based Med. 2017 Dec;22(6):198. doi: 10.1136/ebmed-2017-110858. Epub 2017 Nov 9.

Prostate cancer screening--the evidence, the recommendations, and the clinical implications.

JAMA. 2011 Dec 28;306(24):2721-2. doi: 10.1001/jama.2011.1891.

Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening.

BJU Int. 2003 Dec;92 Suppl 2:97-100. doi: 10.1111/j.1464-410x.2003.04407.x.

Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.

Int J Urol. 2009 May;16(5):458-64. doi: 10.1111/j.1442-2042.2009.02293.x. Epub 2009 Apr 1.

Prostate cancer: estimating the benefits of PSA screening.

Nat Rev Urol. 2009 Jun;6(6):301-3. doi: 10.1038/nrurol.2009.95.

Prostate-specific antigen screening in prostate cancer: perspectives on the evidence.

J Natl Cancer Inst. 2014 Mar;106(3):dju010. doi: 10.1093/jnci/dju010. Epub 2014 Mar 4.

Measuring the importance of PSA velocity.

J Natl Cancer Inst. 2011 Mar 16;103(6):454-61. doi: 10.1093/jnci/djr086. Epub 2011 Mar 10.

Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer.

Urol Oncol. 2009 Nov-Dec;27(6):583-4. doi: 10.1016/j.urolonc.2009.06.011.

Group now advises against routine PSA screening.

JAMA. 2013 Jun 12;309(22):2316. doi: 10.1001/jama.2013.6922.

Prostate Cancer Screening - A Perspective on the Current State of the Evidence.

N Engl J Med. 2017 Mar 30;376(13):1285-1289. doi: 10.1056/NEJMsb1616281.

引用本文的文献

Epidemiological Characteristics of Male Reproductive Cancers in the Republic of Kazakhstan: Ten-Year Trends.

Iran J Public Health. 2022 Aug;51(8):1807-1816. doi: 10.18502/ijph.v51i8.10265.

Long non-coding RNAs and their potential impact on diagnosis, prognosis, and therapy in prostate cancer: racial, ethnic, and geographical considerations.

Expert Rev Mol Diagn. 2021 Dec;21(12):1257-1271. doi: 10.1080/14737159.2021.1996227. Epub 2021 Nov 25.

Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer.

Front Cell Dev Biol. 2021 Feb 25;9:605686. doi: 10.3389/fcell.2021.605686. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Controversies in PSA screening.

Evid Based Med. 2017 Dec;22(6):198. doi: 10.1136/ebmed-2017-110858. Epub 2017 Nov 9.

Prostate cancer screening--the evidence, the recommendations, and the clinical implications.

JAMA. 2011 Dec 28;306(24):2721-2. doi: 10.1001/jama.2011.1891.

Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening.

BJU Int. 2003 Dec;92 Suppl 2:97-100. doi: 10.1111/j.1464-410x.2003.04407.x.

Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.

Int J Urol. 2009 May;16(5):458-64. doi: 10.1111/j.1442-2042.2009.02293.x. Epub 2009 Apr 1.

Prostate cancer: estimating the benefits of PSA screening.

Nat Rev Urol. 2009 Jun;6(6):301-3. doi: 10.1038/nrurol.2009.95.

Prostate-specific antigen screening in prostate cancer: perspectives on the evidence.

J Natl Cancer Inst. 2014 Mar;106(3):dju010. doi: 10.1093/jnci/dju010. Epub 2014 Mar 4.

Measuring the importance of PSA velocity.

J Natl Cancer Inst. 2011 Mar 16;103(6):454-61. doi: 10.1093/jnci/djr086. Epub 2011 Mar 10.

Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer.

Urol Oncol. 2009 Nov-Dec;27(6):583-4. doi: 10.1016/j.urolonc.2009.06.011.

Group now advises against routine PSA screening.

JAMA. 2013 Jun 12;309(22):2316. doi: 10.1001/jama.2013.6922.

Prostate Cancer Screening - A Perspective on the Current State of the Evidence.

N Engl J Med. 2017 Mar 30;376(13):1285-1289. doi: 10.1056/NEJMsb1616281.

引用本文的文献

Epidemiological Characteristics of Male Reproductive Cancers in the Republic of Kazakhstan: Ten-Year Trends.

Iran J Public Health. 2022 Aug;51(8):1807-1816. doi: 10.18502/ijph.v51i8.10265.

Long non-coding RNAs and their potential impact on diagnosis, prognosis, and therapy in prostate cancer: racial, ethnic, and geographical considerations.

Expert Rev Mol Diagn. 2021 Dec;21(12):1257-1271. doi: 10.1080/14737159.2021.1996227. Epub 2021 Nov 25.

Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer.

Front Cell Dev Biol. 2021 Feb 25;9:605686. doi: 10.3389/fcell.2021.605686. eCollection 2021.